| Literature DB >> 35628817 |
Zofia Barcikowska1, Magdalena Emilia Grzybowska2, Piotr Wąż3, Marta Jaskulak1, Monika Kurpas1, Maksymilian Sotomski1, Małgorzata Starzec-Proserpio4, Elżbieta Rajkowska-Labon5, Rita Hansdorfer-Korzon5, Katarzyna Zorena1.
Abstract
BACKGROUND: The study aimed to assess if manual therapy, compared to ibuprofen, impacts the concentration of inflammatory factors, sex hormones, and dysmenorrhea in young womenEntities:
Keywords: CRP; VEGF; estradiol; ibuprofen; manual therapy; physiotherapy; primary dysmenorrhea; progesterone; prostaglandins; young women
Year: 2022 PMID: 35628817 PMCID: PMC9143956 DOI: 10.3390/jcm11102686
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1The enrollment of patients with primary dysmenorrhea.
Figure 2The scheme for carrying out therapy in groups A and B. Modified figure from previous publication [22].
Baseline characteristic of women with primary dysmenorrhea.
| All | Group A | Group B |
| |
|---|---|---|---|---|
| Age (years) | 23 (22; 24.5) | 23.3 ± 2.1 | 23 (21.5; 25) | 0.978 a |
| Body Mass Index (kg/m2) | 21.7 ± 2.8 | 21.9 ± 2.6 | 21.5 ± 3.2 | 0.660 b |
| Severity of dysmenorrhea in NPRS | 8 (7; 8) | 8 (7; 8) | 8 (7; 9) | 0.484 a |
| Duration of menstrual cycle (days) | 28 (28; 30.5) | 28 (28; 29) | 29.5 ± 2.6 | 0.413 a |
| Duration of menstruation (days) | 6 (5; 6) | 5 (5; 6) | 6 (5.5; 6) | 0.016 a |
| Duration of dysmenorrhea (days) | 2 (2; 3) | 2 (2; 3) | 3 (2; 3.5) | 0.046 a |
a—Wilcoxon rank sum test with continuity correction, b—Student’s t-test, Data presented as: median (Q1; Q3), mean ± standard deviation; Abbreviations: NPRS—numeric pain rating scale, Q—quartile.
Concentrations of prostaglandins, CRP, VEGF and sex hormones pre and post manual or ibuprofen treatment.
| Group A | Group B |
| ||
|---|---|---|---|---|
| PGE2 (pg/mL) | Pre | 1044 (633.4; 1368.8) | 985 ± 554 | 0.614 a |
| Post | 1079.08 ± 664.89 | 878.9 ± 499.8 | 0.340 b | |
|
| 0.587 c | 0.201 c | ||
| PGF2α (pg/mL) | Pre | (1245.3; 4615) | 2450 (1595; 3457.5) | 0.791 a |
| Post | 2689.3 ± 1904 | 2030 (1482.5; 3317.5) | 0.945 a | |
|
| 0.409 c | 0.798 c | ||
| VEGF (pg/mL) | Pre | 139.4 ± 99.6 | 135.2 ± 79.3 | 0.895 b |
| Post | 126.6 (65.5; 209.7) | 133.8 ± 71.3 | 0.938 a | |
|
| 0.141 c | 0.754 c | ||
| CRP (mL/L) | Pre | 1.386 ± 0.879 | 1.749 ± 0.764 | 0.215 b |
| Post | 1.673 (1.115; 1.984) | 1.869 ± 1.165 | 0.662 a | |
|
| 0.098 c | 0.977 c | ||
| Estradiol-17β (pg/mL) | Pre | 34 (25; 54.5) | 27 (19.25; 37.75) | 0.229 a |
| Post | 36 (27.5; 53) | 25.462 ± 10.76 | 0.036 a | |
|
| 0.776 c | 0.307 c | ||
| Progesterone (ng/mL) | Pre | 0.415 (0.262; 0.54) | 0.35 (0.25; 0.47) | 0.376 a |
| Post | 0.25 (0.18; 0.33) | 0.246 ± 0.133 | 0.302 a | |
|
| 0.016 c | 0.028 c |
a—Wilcoxon rank sum test with continuity correction, b—Student’s t-test, c—Wilcoxon signed rank test with continuity correction; Data presented as: median (Q1; Q3), mean ± standard deviation. Abbreviations: PGE2—prostaglandin E2; PGF—prostaglandin F2α; VEGF—vascular endothelial growth factor; CRP—C-reactive protein; Q—quartile.
Figure 3Linear model for PGE2 (post dependence on pre). The lines indicate the predicted trend of changes of “pre” and of “post” values (red for group A and green for group B). The dashed grey line is the set of points for which the pre and post values are identical. Points for group A were marked in red, while points for group B were marked in green. Abbreviation: PGE2—prostaglandin E2.
Linear Model for PGE2.
| Estimate | Std. Error |
|
| |
|---|---|---|---|---|
| (Intercept) | 438.410 | 234.764 | 1.867 | 0.079 |
| Group A | 0.558 | 0.174 | 3.212 | 0.005 |
| Multiple R-squared: 0.378 | Adjusted R-squared: 0.341 | |||
| (Intercept) | 155.505 | 162.945 | 0.954 | 0.357 |
| Group B | 0.734 | 0.1454 | 5.053 | 0.0002 |
| Multiple R-squared: 0.662 | Adjusted R-squared: 0.636 | |||
Figure 4Linear model for VEGF (post dependence on pre). The lines indicate the predicted trend of changes of “pre” and of “post” values (red for group A and green for group B). The dashed grey line is the set of points for which the pre and post values are identical. Points for group A were marked in red, while points for group B were marked in green. Abbreviation: VEGF—vascular endothelial growth factor.
Linear model for VEGF.
| Estimate | Std. Error |
|
| |
|---|---|---|---|---|
| (Intercept) | −7.827 | 14.732 | −0.531 | 0.602 |
| Group A | 1.177 | 0.087 | 13.572 | 0.0000000002 |
| Multiple R-squared: 0.916 | Adjusted R-squared: 0.910 | |||
| (Intercept) | 22.242 | 15.449 | 1.44 | 1.74 |
| Group B | 0.825 | 0.099 | 8.30 | 0.000001 |
| Multiple R-squared: 0.841 | Adjusted R-squared: 0.829 | |||
Figure 5Linear model for CRP (post dependence on pre). The lines indicate the predicted trend of changes of “pre” and of “post” values (red for group A and green for group B). The dashed grey line is the set of points for which the pre and post values are identical. Points for group A were marked in red, while points for group B were marked in green. Abbreviation: CRP—C-reactive protein.
Linear Model for CRP.
| Estimate | Std. Error |
|
| |
|---|---|---|---|---|
| (Intercept) | 0.406 | 0.230 | 0.946 | 0.357 |
| Group A | 0.962 | 0.264 | 3.647 | 0.002 |
| Multiple R-squared: 0.439 | Adjusted R-squared: 0.406 | |||
| (Intercept) | 0.245 | 0.637 | 0.385 | 0.707 |
| Group B | 0.928 | 0.337 | 2.767 | 0.016 |
| Multiple R-squared: 0.371 | Adjusted R-squared: 0.322 | |||
Figure 6Linear model for 17-β estradiol (post dependence on pre). The lines indicate the predicted trend of changes of “pre” and of “post” values (red for group A and green for group B). The dashed grey line is the set of points for which the pre and post values are identical. Points for group A were marked in red, while points for group B were marked in green.
Linear Model for 17-β estradiol.
| Estimate | Std. Error |
| ||
|---|---|---|---|---|
| (Intercept) | 16.981 | 3.473 | 4.889 | 0.0002 |
| Group A | 0.530 | 0.053 | 10.024 | 0.00000003 |
| Multiple R-squared: 0.863 | Adjusted R-squared: 0.854 | |||
| (Intercept) | 0.0002 | 4.059 | 4.648 | 0.0009 |
| Group B | 0.194 | 0.084 | 2.315 | 0.043 |
| Multiple R-squared: 0.349 | Adjusted R-squared: 0.284 | |||
Severity of dysmenorrhea pre and post manual or ibuprofen treatment.
| Group A | Group B |
| ||
|---|---|---|---|---|
| Severity of dysmenorrhea | Pre | 8 (7; 8) | 8 (7; 9) | 0.484 a |
| Post | 4.9 ± 2.4 | 3.9 ± 2.8 | 0.265 b | |
|
| 0.000 c | 0.002 c |
a—Wilcoxon rank sum test with continuity correction, b—Student’s t-test, c—Wilcoxon signed rank test with continuity correction; Data presented as: median (Q1; Q3), mean ± standard deviation. Abbreviations: Q—quartile.
Number of muscles with dysfunction pre and post manual or ibuprofen treatment.
| Group A | Group B |
| ||
|---|---|---|---|---|
| Number of muscles with dysfunction | Pre | 12 (11; 13) | 12 (12; 13) | 0.641 a |
| Post | 8.75 ± 2.552 | 12 (11; 12.5) | 0.002 a | |
|
| 0.0005 a | 0.112 a |
a—Wilcoxon rank sum test with continuity correction, Data presented as: median (Q1; Q3), mean ± standard deviation. Abbreviations: Q—quartile.
Figure 7Correlation between 17-beta estradiol and CRP. Kendall’s tau (τ) values and Spearman’s rank correlation rho (ρ) are shown. The determined values of the coefficients are statistically significant.
Figure 8Correlation between progesterone and CRP. Kendall’s tau (τ) values and Spearman’s rank correlation rho (ρ) are shown. The determined values of the coefficients are statistically significant.